KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Cash & Current Investments (2017 - 2026)

Guardant Health's Cash & Current Investments history spans 9 years, with the latest figure at $1.2 billion for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 43.05% to $1.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 billion, a 43.05% increase, with the full-year FY2025 number at $1.2 billion, up 43.05% from a year prior.
  • Cash & Current Investments hit $1.2 billion in Q4 2025 for Guardant Health, up from $580.0 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for GH hit a ceiling of $1.9 billion in Q1 2021 and a floor of $580.0 million in Q3 2025.
  • Historically, Cash & Current Investments has averaged $1.1 billion across 5 years, with a median of $960.2 million in 2022.
  • Biggest five-year swings in Cash & Current Investments: surged 273.1% in 2021 and later crashed 52.35% in 2022.
  • Tracing GH's Cash & Current Investments over 5 years: stood at $932.7 million in 2021, then increased by 8.41% to $1.0 billion in 2022, then grew by 15.57% to $1.2 billion in 2023, then decreased by 28.12% to $840.0 million in 2024, then surged by 43.05% to $1.2 billion in 2025.
  • Business Quant data shows Cash & Current Investments for GH at $1.2 billion in Q4 2025, $580.0 million in Q3 2025, and $629.1 million in Q2 2025.